Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cat allergy immunotherapy - Circassia

Drug Profile

Cat allergy immunotherapy - Circassia

Alternative Names: Cat allergen vaccine - Circassia; Cat peptide allergen desensitisation; Cat Synthetic Peptide Immuno-Regulatory Epitopes; Cat-PAD; Cat-SPIRE; ToleroMune; ToleroMune Cat

Latest Information Update: 13 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Circassia
  • Class Allergens; Antiallergics; Cat allergy immunotherapies; Peptide vaccines; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Allergic rhinoconjunctivitis
  • Discontinued Hypersensitivity

Most Recent Events

  • 18 Jul 2018 National Institute of Allergy and Infectious Diseases and Circassia completes a phase II trial for Allergic rhinoconjunctivitis (cat allergy) in Canada (NCT02311413)
  • 24 Jun 2018 Biomarkers information updated
  • 30 Aug 2017 Circassia completes a phase III follow-on trial for Allergic rhinoconjunctivitis in USA, Canada, Belgium, Czech Republic, Germany, Hungary, Poland, Slovakia and Russia (NCT02040844)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top